tbuckley/cabot-search huggingface dataset:
The role of transarterial embolization and chemoembolization (TACE) for palliative treatment of recurrent and metastatic abdominal mesenchymal tumors (RMAMT): The Brazilian Tertiary A.C. Camargo Cancer Center (ACCCC) experience.
Authors: Ulisses Ribaldo Nicolau, Charles Edouard Zurstrassen, Tiago Cordeiro Felismino, Victor Hugo Fonseca Jesus, Celso Lopes Mello, Nirvana Formiga, Aldo A. Dettino, Helano C. Freitas, Augusto Akikubo Rodrigues Pereira
Journal: Journal of Clinical Oncology (2014)

e21520 Background: TACE local palliative therapy has been increasingly employed in clinical practice for managing patients (pts) harboring chemotherapy (CT) refractory RMAMT. Relief of symptoms, e.g., pain and bleeding, comprises the majority of TACE indications in this highly select population. Despite the greater use of these procedures in clinical practice, a clear measurement of benefit is lacking. The aim of this report is to discuss the elaboration of a potential end point to be tested in a prospective setting in order to estimate a measurable benefit of this strategy. Methods: All ACCCC pts diagnosed with RMAMT who underwent TACE between January 2011 and November 2013 were retrospectively identified. Patients had to present a histologically confirmed diagnosis of sarcoma, with radiological confirmation of RMAMT. Medical archives provided all data regarding demographic characteristics, efficacy, and tolerability. Results: Twelve consecutive pts, 6 male/6 female, ages ranging from 20 to 89 (median 52.5) were studied. Median follow-up was 6.6 months. Main primary sites were abdominal-pelvic in 8 and limb in 3 pts; 9 high grade. Most frequent histological types were leiomeiosarcoma in 3pts, liposarcoma in 3 pts, and angiosarcoma in 2 pts. Eleven of 12 pts received previous CT, with a median of 2 lines of treatment. At time of TACE, ECOG performance status was 0-1 in 8 pts and 2-3 in 4 pts. Pain and abdominal enlargement/discomfort, were the clinical indication for TACE in 6 and 3 cases respectively. Target lesions were located in retroperitonium and liver in most cases. Radiological tumor shrinkage or necrosis, and symptom relief, were recorded in 6 pts. Median overall survival post-TACE was 4.7 months, ranging from 1.1 to 8.2 months. Adverse events demanding hospitalization included hepatic abscess in 2 pts, pancreatitis, and acute pulmonary edema in 1 pt each. No treatment-related death was recorded. Conclusions: TACE is feasible and may be a useful tool in management of symptomatic pts with RMAMT. ACCCC will develop a prospective trial focusing on quality of life in this specific population.
Association of Long-term Exercise Training With Risk of Falls, Fractures, Hospitalizations, and Mortality in Older Adults
Authors: Philipe de Souto Barreto, Yves Rolland, Bruno Vellas, Mathieu Maltais
Journal: JAMA Internal Medicine (2018)

Long-term exercise benefits on prevalent adverse events in older populations, such as falls, fractures, or hospitalizations, are not yet established or known.To systematically review and investigate the association of long-term exercise interventions (≥1 year) with the risk of falls, injurious falls, multiple falls, fractures, hospitalization, and mortality in older adults.PubMed, Cochrane Central Register of Controlled Trials, SportDiscus, PsychInfo, and Ageline were searched through March 2018.Exercise randomized clinical trials (RCTs) with intervention length of 1 year or longer, performed among participants 60 years or older.Two raters independently screened articles, abstracted the data, and assessed the risk of bias. Data were combined with risk ratios (RRs) using DerSimonian and Laird's random-effects model (Mantel-Haenszel method).Six binary outcomes for the risk of falls, injurious falls, multiple falls (≥2 falls), fractures, hospitalization, and mortality.Forty-six studies (22 709 participants) were included in the review and 40 (21 868 participants) in the meta-analyses (mean [SD] age, 73.1 [7.1] years; 15 054 [66.3%] of participants were women). The most used exercise was a multicomponent training (eg, aerobic plus strength plus balance); mean frequency was 3 times per week, about 50 minutes per session, at a moderate intensity. Comparator groups were often active controls. Exercise significantly decreased the risk of falls (n = 20 RCTs; 4420 participants; RR, 0.88; 95% CI, 0.79-0.98) and injurious falls (9 RTCs; 4481 participants; RR, 0.74; 95% CI, 0.62-0.88), and tended to reduce the risk of fractures (19 RTCs; 8410 participants; RR, 0.84; 95% CI, 0.71-1.00; P = .05). Exercise did not significantly diminish the risk of multiple falls (13 RTCs; 3060 participants), hospitalization (12 RTCs; 5639 participants), and mortality (29 RTCs; 11 441 participants). Sensitivity analyses provided similar findings, except the fixed-effect meta-analysis for the risk of fracture, which showed a significant effect favoring exercisers (RR, 0.84; 95% CI, 0.70-1.00; P = .047). Meta-regressions on mortality and falls suggest that 2 to 3 times per week would be the optimal exercise frequency.Long-term exercise is associated with a reduction in falls, injurious falls, and probably fractures in older adults, including people with cardiometabolic and neurological diseases.
Impact of UGT1A1 gene polymorphism on survival in metastatic colorectal cancer patients treated with irinotecan-containing therapy.
Authors: Hiromichi Shirasu, Kentaro Yamazaki, Mitsuhiro Furuta, Masahiro Kawahira, Takeshi Kawakami, Yukio Yoshida, Sadayuki Kawai, Satoshi Hamauchi, Akiko Todaka, Takahiro Tsushima, Nozomu Machida, Tomoya Yokota, Akira Fukutomi, Yusuke Onozawa, Hirofumi Yasui
Journal: Journal of Clinical Oncology (2018)

813 Background: UGT1A1 polymorphisms have been reported to be associated with increased irinotecan (IRI)-induced toxicity. However, influence of the polymorphisms on survival in metastatic colorectal cancer (mCRC) patients (pts) treated with IRI-containing therapy remains controversial. Methods: We retrospectively reviewed data of consecutive mCRC pts who received FOLFIRI/IRI with or without an anti-VEGF agent as 2nd line therapy at the Shizuoka Cancer Center between April 2008 and December 2015. The primary selection criteria were histologically confirmed adenocarcinoma, prior history of oxaliplatin-containing therapy, and adequate organ function. UGT1A1 polymorphisms were screened and pts with homozygous (*6/*6, *28/*28) or compound heterozygous (*6/*28) were excluded. Results: Among 103 pts found eligible for this analysis, 63 were wild type (W) (−/−) for UGT1A1, and 40 were heterozygous type (H) (-/*6, -/*28), with the following characteristics: median age (range), 60 (30–77) vs 67 (37–84); male/female, 41/22 vs 18/22; PS 0/1/2, 40/21/2 vs 21/18/1; tumor location right/left, 16/47 vs 9/31; peritoneal metastasis −/+, 49/14 vs 33/7; disease status metastasis/recurrence, 49/14 vs 23/17; RAS wild type/mutant, 25/37 vs 18/21; IRI regimen doublet/mono, 51/12 vs 33/7; anti-VEGF agent use −/+, 16/47 vs 12/28; and median IRI dose intensity, 63.7 vs 60 mg/m2/week. Incidences of grade 3/4 neutropenia, febrile neutropenia, and diarrhea in W/H pts were 36%/48%, 5%/9%, 5%/13% (initial IRI dose 180 mg/m2). Median PFS was 6.2 M in W, and 3.9 M in H (p = 0.36). Median OS was 12.1 M in W and 10.9 M in H (p = 0.86). RR was 13% in W, and 10% in H (p = 0.68). DCR was 81% in W, and 58% in H (p = 0.012). Multivariate analysis identified no liver-limited disease, disease status (metastatic), UGT1A1 H type, IRI monotherapy, and no anti-VEGF as independent predictors of poorer PFS (HR 1.76, 2.01, 1.67, 2.17, 2.58), and initial dose of CPT &lt; 180mg/m2 and no anti-VEGF as independent predictors of poorer OS (HR 1.85 and 1.85). UGT1A1 polymorphism was not detected as an independent predictor of RR or DCR. Conclusions: UGT1A1 polymorphism may be useful in predicting PFS in mCRC pts treated with IRI-containing therapy.
The Talking Cure
Authors: Jack Coulehan
Journal: Annals of Internal Medicine (2018)

Ad Libitum1 January 2019The Talking CureJack Coulehan, MD, MPHJack Coulehan, MD, MPHSetauket, New York (J.C.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M18-1488 Audio Reading - “The Talking Cure” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "The Talking Cure," by J. Coulehan. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail for David Pearson, MDAt eighty-one, my friend, who once was toldhe'd never graduate in medicinebecause his heart was tender, climbs the stairsafter seeing his last patient. For yearshe's helped a retired lieutenant examinethe slippage of his inner knots by talking.We sip iced tea. They don't teach the talkingtreatment anymore. We used to be toldthat words matter. Remember? He's examinedsyllables and silence as his medicinefor decades. His cheeks ravaged by the yearson steroids, twitch with dampness, and he stareswith sharp ... Author, Article, and Disclosure InformationAffiliations: Setauket, New York (J.C.)Current Author Address: Jack Coulehan, MD, MPH; e-mail, [email protected]com. PreviousarticleNextarticle Advertisement Audio Reading - “The Talking Cure” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "The Talking Cure," by J. Coulehan. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 1 January 2019Volume 170, Issue 1Page: 73KeywordsAdolescentsGraduate medical educationGratitudeHeartSteroidsTea ePublished: 1 January 2019 Issue Published: 1 January 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Outcomes in stage IS testicular seminoma: A population-based analysis of 323 patients.
Authors: Kamran A. Ahmed, Richard Wilder
Journal: Journal of Clinical Oncology (2014)

e15531 Background: Due to the rarity of stage IS testicular seminoma, it is unlikely that prospective clinical trials will be conducted to determine the best treatment. Consequently, we retrospectively assessed outcomes in stage IS testicular seminoma patients using a population-based analysis. Methods: One thousand one hundred and fifty-two stage I testicular seminoma patients with normal alpha-fetoprotein levels were identified between 1998 and 2005 in the Surveillance, Epidemiology, and End Results (SEER) database. Three hundred and twenty-three of these patients had persistent elevations of their serum beta subunit of human chorionic gonadotropin (bHCG) and/or lactate dehydrogenase (LDH) level post-orchiectomy, i.e., “stage IS” disease. Results: Median follow-up was 86 months. Twenty-eight % of stage I pure testicular seminoma patients had stage IS disease. Six hundred and sixteen (53%) patients had IA disease and 178 (15%) had IB disease. Nineteen % of stage I patients had an elevated LDH level and 15% of stage I patients had an elevated bHCG level. LDH and bHCG did not predict overall (OS) or cause-specific (CSS) survival (p=.31 and p=.51, respectively). Radiation therapy (RT) was delivered to 71% of stage IS patients. There was a significant decrease in utilization of adjuvant RT in IS patients from 1998 (100%) to 2005 (58%, p=.01). There was no significant difference in 5-year and 10-year OS between stage IA (99% and 96%), IB (98%), and IS (98% and 96%) patients (p=.55). There was no significant difference in OS between IA, IB, and IS patients who did (p=.70) or did not receive radiation (p=.44). Conclusions: There was decreasing utilization of adjuvant RT in the United States in stage IS testicular seminoma patients between 1998 and 2005. Longer follow up is necessary to assess the impact of second malignancies on OS.
Primary resistance to sunitinib in metastatic renal cell carcinoma: Incidence, clinical characteristics, and predicting factors.
Authors: Sung Hee Lim, Ji Yun Lee, Min-Young Lee, Donghoon Han, Moonjin Kim, Sungmin Kim, Hyun Ae Jung, In Gyu Hwang, Jun Ho Ji, Sung Yong Oh, Jong-Mu Sun, Ho Yeong Lim, Se Hoon Park
Journal: Journal of Clinical Oncology (2014)

e15570 Background: In a subset of patients with metastatic renal cell carcinoma (RCC), primary resistance to first VEGF targeted therapy is not fully understood, and the optimal treatment approach for these patients is still controversial. This study was aimed to characterize the primary sunitinib resistant patients and associated predicting factors. Methods: A total of 134 patients with recurrent or metastatic RCC, who were initially treated with sunitinib, consecutively selected from 4 centers in Korea, between January 2008 and March 2013. Patients in whom progressive disease (PD) was the best response during treatment with sunitinib were included in the primary sunitinib resistant group. Results: Among 134 patients, 33 (25%) patients primary resistant to sunitinib with a median age of 59 years (range, 28-78) were identified. Most patients had clear cell histology (95.4%) and good ECOG performance status (0, 1) (92.5%). According to MSKCC risk, 27% of patients were at favorable risk, 70% at intermediate risk, and 3% at poor risk. Univariate analysis revealed that MSKCC poor risk, anemia, elevated LDH, hypercalcemia, neutrophilia, poor ECOG PS(≥2), and higher number of distant metastatic disease (≥3) were independent factors associated with primary resistant disease. Neutrophilia (OR=7.7, p=0.018) and more than two distant metastatic disease (OR=5.7, p=0.002) were significant predictors of primary resistant disease on multivariate analysis. There was statistically significant difference with regard to overall survival (median, 11.7 vs. 31.1 month; p=0.0006) and progression free survival (median, 2.4 vs. 12.5 month; p<0.0001) between the patients with and without primary resistance disease. Conclusions: Primary resistance to sunitinib treatment is associated with a dismal prognosis in metastatic RCC patients. Along with above clinical predicting factors, more understanding of the underlying mechanism and molecular markers for detecting the primary resistant disease are needed.
Abstract 13484: The HECT Type E3 Ligase ITCH Ameliorates Left Ventricular Remodeling and Mortality after Myocardial Infarction
Authors: Otaki Yoichiro, Tetsu Watanabe, Hiroki Takahashi, Taro Narumi, Shinpei Kadowaki, Yuki Honda, Takanori Arimoto, Tetsuro Shishido, Takuya Miyamoto, Isao Kubota
Journal: Circulation (2014)

Background: Oxidative stress and subsequent cardiomyocyte apoptosis are relavant factors myocardial remodeling in myocardial infarction. HECT-type ubiquitin E3 ligase ITCH is an enzyme which plays a pivotal role in posttranslational modification by ubiquitin proteasomal protein degradation. Thioredoxin-interacting protein (TXNIP) is a negative regulator of thioredoxin system, scavenging reactive oxygen species (ROS). In the present study, we examined whether ubiquitin E3 ligase ITCH attenuates myocardial infarction through ubiquitin proteasomal TXNIP degradation. Methods and Results: We confirmed protein interaction between TXNIP and ITCH in cardiomyocytes by immunoprecipitation. Overexpression of ITCH increased proteasomal TXNIP degradation and augmented thioredoxin activity, which led to inhibition of ROS generation, p38 mitogen-activated protein kinase, p53, and subsequent intrinsic cardiomyocyte apoptosis after hydrogen peroxide stimulation. Conversely, siRNA-mediated inhibition of ITCH inhibited TXNI...
Survival and Time to Response with Frontline Hypomethylating Agents in AML
Authors: Jing Ai, Danielle Boselli, Lauren M. Bohannon, Thomas G. Knight, Brittany Ragon, Belinda Rene Avalos, Edward A. Copelan, James T Symanowski, Jonathan M. Gerber, Michael R. Grunwald
Journal: Blood (2018)
Dose escalation with high-dose-3D-conformal (HD-3D-CRT) or low-dose 3D-conformal radiotherapy PLUS HDR brachytherapy (LD-3D-CRT+HDR-B) for intermediate- or high-risk prostate cancer: Higher disease control and survival with lower toxicity.
Authors: Benjamin Guix, Jose Maria Bartrina, Jose Ignacio Tello, Luis Quinzaños, Teresa Maria Lacorte, Ines Guix, Guillermo Galdon, Marc Espino, Teresa Guix
Journal: Journal of Clinical Oncology (2014)

5087 Background: To report early and late toxicity and biochemical outcome in a prospective series of 445 patients with intermediate- or high-risk clinically localized prostate cancer treated with either HD-3D-CRT or with LD-3D-CRT+HDR-B. Methods: Between 12/1999 and 10/2005, 445 patients (pts) with PSA›10, Gleason score›6 and/or T2b-T3 N0 M0 prostate cancer entered the study. Pts were prospectively assigned to one of the two treatment groups: 76 Gy HD-3D-CRT to the prostate in 38 fractions (group 1; 223 patients) or 46 Gy LD-3D-CRT+ 16 Gy HDR-B given in 2 fractions of 8 Gy (group 2, 222 patients), limiting the maximum rectal dose to 85% of the prescribed dose. Both groups were well balanced taking into account patient’s as well as tumors’ characteristics. Toxicities were scored by the EORTC /RTOG morbidity grading scales. Special attention to local, regional or distant recurrence, survival, late effects, PSA and testosterone levels and quality of life was done. Results: All pts completed treatment. None pts included in the group 1 or 2 experienced grade 3 or more rectal toxicity. 28 pts of group 1 (12.5%) and 6 pts of group 2 (2.7%) developed grade 2 rectal toxicity (rectal bleeding or urgency). 15 pts in group 1 (6.7%) and 3 pts in group 2 (1.3%) developed grade 1 rectal bleeding (less than 2 times/week). With a mean follow-up of 96 months, the 10-year free-from-failure survival was 90.7% and 98.3% (p<0.002) in group 1 and 2 respectively; free-from-metastases survival 96.9% and 97.9% (p<0,008)for group 1 and 2 respectively; and cause-specific survival 97.4% and 98.3% (p<0.09). Conclusions: High-dose 3D-EBRT + HDR brachytherapy was a safe and effective method of escalating the dose to the prostate without increasing the risk of late effects. Acute as well as late rectal complications were significantly reduced with the combined treatment, compared with what was observed with high-dose conventional, 3D-conformal radiotherapy. Control rates were better with in the HDR-boosted patients as expected by higher effective-dose.
Abstract 17828: 89Zr-Bevacizumab PET Detects Arteriolar Remodeling In Experimental Pulmonary Hypertension
Journal: Circulation (2017)

Introduction: Pulmonary arterial hypertension (PAH) is a disease of progressive pulmonary vascular remodeling and obliteration with poor prognosis despite current therapies. Outcomes in PAH might b...
Plurihormonal Pituitary Tumor of Pit-1 and SF-1 Lineages, with Synchronous Collision Corticotroph Tumor: a Possible Stem Cell Phenomenon
Authors: Karen M. Tordjman, Yona Greenman, Zvi Ram, Dov Hershkovitz, Orna Aizenstein, Ofra Ariel, Sylvia L. Asa
Journal: Endocrine Pathology (2019)
Tissue engineered human prostate microtissues reveal key role of mast cell-derived tryptase in potentiating cancer-associated fibroblast (CAF)-induced morphometric transition in vitro
Authors: Brooke A. Pereira, Natalie L. Lister, Kohei Hashimoto, Linda Teng, Maria Flandes-Iparraguirre, Angelina Eder, Alvaro Sanchez-Herrero, Birunthi Niranjan, Mark Frydenberg, Melissa M. Papargiris, Mitchell G. Lawrence, Renea A. Taylor, Dietmar W. Hutmacher, Stuart J. Ellem, Gail P. Risbridger, Elena M. De-Juan-Pardo
Journal: Biomaterials (2019)
MicroRNAs in T cell acute lymphoblastic leukemia
Authors: Elizabeth Nakae, John Cornell, George Calin, Brad Pollock, Carlo Croce, Alice Yu, Mitchell Diccianni
Journal: Cancer Research (2007)

4519  Treatment success for Acute Lymphoblastic Leukemia (ALL), both B- and T-cell, is one of cancer research’s greatest achievements. However, while molecular determinants of outcome have been identified for B-ALL, no useful prognostic factors for T-ALL have been identified. MicroRNAs (miRNAs) are small 21-23 nucleotide non-coding RNA molecules that can positively or negatively regulate gene expression and have recently been shown to have prognostic potential. Using a miRNA gene chip to investigate the involvement of miRNA in T-ALL, we analyzed the miRNA expression in RNA from 41 individual T-ALL cell samples, 4 normal thymocyte samples and 9 normal blood mono-nuclear cell (MNC) samples hybridized against arrays containing 368 (161 human or 460 (235 human) miRNA genes. Differentially expressed miRNAs were observed in T-ALL vs. the normal samples. Unsupervised hierarchical clustering revealed homogenous but distinctive expression profiles for each sample type, with T-ALL samples falling into a cluster that was distinct from that of MNCs or thymocytes. Using LInear Models for MicroArrays (LIMMA) to evaluate differential expression between T-ALL and thymocytes, we identified 43 genes that had statistically significant differences in expression levels between the two groups (P   In conclusion, we have characterized the miRNA expression profile of T-ALL and have identified a number or miR genes that are highly downregulated vs. normal thymocytes. The combined downregulation of related miR genes on 9q22 suggests downregulation of the entire primary transcript is occurring in T-ALL. However, the observation that related genes on 19p13 are also among the most significantly down-regulated miR genes in T-ALL increases the likelihood that one or more genes of this cluster may play a role in T-ALL biology.
Use of docetaxel in combination with octreotide as a synergistic combination for prostate cancer with apoptotic and antiangiogenic effects.
Authors: Burcak Karaca, Harika Atmaca, Emir Bozkurt, Canfeza Sezgin, Bulent Karabulut, Ruchan Uslu
Journal: Journal of Clinical Oncology (2014)

e13515 Background: In this study, we investigated the possible cytotoxic and apoptotic effects of docetaxel, a standard treatment for hormone refractory prostate cancer, in combination with octreotide in prostate cancer cell lines. Pivotal proteins of angiogenesis were also studied with this combination. Methods: Human prostate cancer cells (DU-145, PC-3 and LNCaP) were treated with the increasing concentrations of drugs alone or in combination for 72h. XTT assay was done to assess cytotoxicity. Apoptosis was shown by DNA fragmentation and Caspase 3/7 activity assays. Changes in apoptosis-related protein expressions were investigated by apoptosis antibody array. The protein levels of pivotal angiogenic molecules, PDGF, FGF,VEGF were detected by Western blot analysis. Results: 10 nM docetaxel+10 nM octreotide combination treatment resulted in synergistic cytotoxicity in a dose-dependent manner in all prostate cancer cells (p<0.05). DNA fragmentation and caspase 3/7 activity were also induced in a dose-dependent manner (p<0.05). Changes in apoptosis related proteins in prostate cancer cells exposed to combination were shown in the Table (p<0.05). There were also significant decreases in protein levels of angiogenic PDGF, FGF, VEGF proteins in combination treated prostate cancer cells. Conclusions: Based on these findings, docetaxel/octreotide combination with synergistic cytotoxic, apoptotic and anti-angiogenic effects might demonstrate a promising combination treatment for prostate cancer in future. Fold change Protein Octreotide Docetaxel Combination (a) Bax 1.8 1.6 3.2 Bad 1.25 1.6 1.93 Fas 3.2 4.6 10.8 Cleaved-Caspase-3 2.3 4.2 8.8 FADD 2.6 2.4 4.7 Phospho p53 1.7 2.3 5.6 Cytochrome c 2.1 3.3 4.8 Smac/DIABLO 3.4 4.7 7.6 XIAP -2.2 -3.6 -4.1 (b) Cleaved-Caspase-3 2 2.1 4.3 Bax 2.6 1.2 2.9 Bcl-2 -2.5 -2.2 -4.6 Bcl-xL -3.2 -2.6 -4.2 P53 2.2 1.8 2.7 Rad17 1.3 1.6 2.2 SMAC/Diablo 2.6 1.4 3.2 cIAP-2 -1.7 -1.1 -2.3 Cytochrome c 2.6 1.8 3.4 HTRA2/Omi 1.4 1.6 2.8 Phospho-p53 2.4 2.3 3.6 (c) Bax 2.2 1.8 4.4 Bad 3 2.1 5.2 Fas 2 1.6 3.2 FADD 2.3 1.9 3.6 TRAIL-R2 2.4 1.8 3.9 Bcl-2 -2.1 -3.4 -5.6 Bcl-xL 1.7 2.2 -3.7 HSP27 -1.2 -2.3 -4.1 Cleaved-Caspase-3 3.4 2.1 7.4 Phospho p53 2.4 3.4 5.5 TNF R1 1.7 2.3 4.6